Table of Contents 1. Analyst View 2. Research Methodology 3. Biologics Market Outlook to 2020 3.1 Market Size 3.2 Market Segmentation 4. Global Biosimilars Market Outlook 2020 4.1 Market Size 4.2 Market Segmentation by Application 4.2.1 Erythropoietin (EPO) 4.2.2 Human Growth Hormone (HGH) 4.2.3 Granulocyte- Colony Stimulating Factor (G-CSF) 4.2.4 Monoclonal Antibody (mAb) 4.2.5 Insulin 4.2.6 Interferon (IFN) 4.3 Market Segmentation by Geography 4.3.1 Europe 4.3.2 Asia-Pacific 4.3.3 Others 5. Market Drivers and Challenges 5.1 Drivers 5.1.1 Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market 5.1.2 Shrinking Healthcare Budgets to Carve Way for Biosimilars 5.1.3 Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars 5.2 Challenges 5.2.1 Need for the Development of Manufacturing Capabilities 5.2.2 Greater Litgation Risk 5.2.3 High Cost of Development Accompanied with Low Adoption 5.2.4 Interchangeability/ Substitutability 6. Market Trends and Developments 6.1 Plant based Manufacturing Platforms for Biosimilars 6.2 Developing Economies Emerge as Potential Markets for Biosimilar Production 7. Mergers and Acquisitions 8. Porters Five Forces Model 9. Competitive Landscape 9.1 Market Share of Major Players 9.2 Profiles 9.2.1 Biocad 9.2.2 Celltrion 9.2.3 Dong-A Pharmaceutical Co., Ltd 9.2.4 Hospira 9.2.5 Intas 9.2.6 Sandoz 9.2.7 Stada Arzneimittel 9.2.8 Teva 10. Future Outlook List of Figures
Figure 3-1: Global - Biologics Market (Billion US$), 2014-2020 Figure 3-2: Share of Biologics in Sales of Top 100 Pharma Products Figure 3-3: Global - Biologics Market by Segment (%), 2014 Figure 4-1: Global - Biosimilars Market (Billion US$), 2014-2020 Figure 4-2: Global - Biosimilars Market by Key Segment (%), 2014 Figure 4- 3: Global - Biosimilars Market by Key Segment (%), 2020 Figure 4-4: Global - Erythropoietin Biosimilars Market (Million US$), 2014 & 2020 Figure 4-5: Global - HGH Biosimilars Market (Million US$), 2014 & 2020 Figure 4-6: Global - G-CSF Biosimilars Market (Million US$), 2014 & 2020 Figure 4-7: Global - mAb Biosimilars Market (Million US$), 2014 & 2020 Figure 4-8: Global - Insulin Biosimilars Market (Million US$), 2014 & 2020 Figure 4-9: Global - Interferon Biosimilars Market (Million US$), 2014 & 2020 Figure 4-10: Europe - Biosimilars Market (Million US$), 2014-2020 Figure 4-11: Europe - Biosimilars Market by Country (%), 2014 Figure 4-12: Asia - Pacific - Biosimilars Market (Billion US$), 2014-2020 Figure 4-13: Asia - Pacific - Biosimilars Market by Country (%), 2014 Figure 4-14: Others - Biosimilars Market (Billion US$), 2014-2020 Figure 5-1: World¡¯s Best Selling Biologics and their Patent Expiry in the US Figure 9-1: Market Share of Major Players in the Biosimilar Industry, 2014 Figure 9-2: Hospira - Breakdown of Revenue by Geographic Segment (%), 2013 Figure 9-3: Hospira - Breakdown of Revenue by Industry Segment (%), 2013 Figure 9-4: Sandoz - Global Sales (Billion USD), 2011-2013 Figure 9-5: Sandoz - Breakdown of Revenue by Geographic Segment (Billion USD), 2011-2013 List of Tables
Table 4-1: Global - Patent Expiry Status of EPOs Table 4-2: Global - Biosimilar EPOs Approved for Marketing Table 4-3: Global - Biosimilar EPOs in Pipeline Table 4-4: Global - Biosimilar HGH Approved for Marketing Table 4-5: Global - Biosimilar HGH in Pipeline Table 4-6: Global - Biosimilar G-CSF Approved for Marketing Table 4-7: Global Biosimilar G-CSF Market - Key Players by Rank Table 4-8: Global - Biosimilar G-CSF in Pipeline Table 4-9: Global - Patent Expiry Status of G-CSF Table 4-10: Global - Biosimilar mAbs Approved for Marketing Table 4-11: Global Biosimilar mAb Market - Key Players by Rank Table 4-12: Global - Biosimilar mAbs in Pipeline Table 4-13: Global - Patent Expiry Status of mAbs Table 4-14: Global - Biosimilar Insulin Approved for Marketing Table 4-15: Global Biosimilar Insulin Market - Key Players by Rank Table 4-16: Global - Biosimilar Insulin in Pipeline Table 4-17: Global - Patent Expiry Status of Insulin Table 4-18: Global - Biosimilar Interferons Approved for Marketing Table 4-19: Global - Biosimilar Interferons in Pipeline Table 4-20: Global - Patent Expiry Status of Interferons Table 7-1: Global - Major M&A Activity in the Past Year Table 9-1: Biocad - Biosimilars Approved for Marketing Table 9-2: Biocad - Biosimilars in Pipeline Table 9-3: Biocad - Strengths & Weaknesses Table 9-4: Celltrion - Key Financials (Million KRW), 2011-2013 Table 9-5: Celltrion - Biosimilars Approved for Marketing Table 9-6: Celltrion - Biosimilars in Pipeline Table 9-7: Celltrion - Strengths & Weaknesses Table 9-8: Dong-A Pharmaceutical - Key Financials (Billion Won), 2011-2013 Table 9-9: Dong-A Pharmaceutical - Biosimilars in Pipeline Table 9-10: Dong-A Pharmaceutical - Strengths & Weaknesses Table 9-11: Hospira - Key Financials (Million Dollars), 2011-2013 Table 9-12: Hospira - Biosimilars Approved for Marketing Table 9-13: Hospira - Biosimilars in Pipeline Table 9-14: Hospira - Strengths & Weaknesses Table 9-15: Intas - Biosimilars Approved for Marketing Table 9-16: Intas - Biosimilars in Pipeline Table 9-17: Intas - Strengths & Weaknesses Table 9-18: Sandoz - Biosimilars Approved for Marketing Table 9-19: Sandoz - Biosimilars in Pipeline Table 9-20: Sandoz - Strengths & Weaknesses Table 9-21: Stada - Biosimilars Approved for Marketing Table 9-22: Stada - Biosimilars in Pipeline Table 9-23: Stada - Strengths & Weaknesses Table 9-24: Teva - Biosimilars Approved for Marketing Table 9-25: Teva - Strengths & Weaknesses
|